PWAM
PTCT icon

Private Wealth Asset Management’s PTC Therapeutics PTCT Stock Holding History

Private Wealth Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200
Closed -$13.6K – 955
2026
Q1 		$13.6K Hold
200
– – ﹤0.01% 639
2025
Q4 		$15.2K Hold
200
– – ﹤0.01% 597
2025
Q3 		$12.3K Hold
200
– – ﹤0.01% 610
2025
Q2 		$9.77K Buy
+200
New +$9.49K ﹤0.01% 667

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Private Wealth Asset Management's PTCT Position: Q2 2026 in Review

Private Wealth Asset Management sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 200 shares — an estimated $13.6K sold.

Private Wealth Asset Management first reported a position in PTCT in Q2 2025 and held it in 4 quarters. The position peaked at $15.2K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Private Wealth Asset Management reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Private Wealth Asset Management sold 200 PTC Therapeutics shares in Q2 2026, an estimated $13.6K.
  • Private Wealth Asset Management first reported a position in PTC Therapeutics in Q2 2025 and held it in 4 quarters.
  • Private Wealth Asset Management's PTC Therapeutics position peaked at $15.2K in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Private Wealth Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.